ENTA — Enanta Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $339.02m
- $275.90m
- $65.32m
Brief: Enanta Pharmaceuticals Q3 Revenue USD 18.892 Million Vs. IBES Estimate USD 18.1 Million
Enanta Pharmaceuticals Inc expected to post a loss of $2.33 a share - Earnings Preview
Brief: Enanta Pharmaceuticals Announces Positive Data From A Phase 1 Clinical Study Of EDP-323, An Oral, L-Protein Inhibitor In Development For Treatment Of RSV
U.S. STOCKS ON THE MOVE-Airbnb, Y-mAbs Therapeutics, Neuronetics
Enanta Pharma falls after brokerages cut PT on mixed COVID drug trial data
U.S. RESEARCH ROUNDUP- Cigna Group, McKesson, Zscaler
Brief: Enanta Pharmaceuticals Reports Financial Results For Second Quarter
Brief: Enanta Pharmaceuticals Reports Positive Results From Phase 2 Sprint Trial Evaluating EDP-235 In Standard Risk Patients With Covid-19
Enanta Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Enanta Pharmaceuticals posts Q2 revenue USD 17.795 million
Enanta Pharmaceuticals Inc expected to post a loss of $1.98 a share - Earnings Preview
Brief: Enanta Pharmaceuticals Announces Sale Of A Portion Of Global Royalties On Mavyret® (U.S.)/Maviret® (Ex-U.S.) (Glecaprevir/Pibrentasvir) To Omers Life Sciences For $200 Million
Brief: Enanta Pharmaceuticals Presents Data For Its Covid-19 And Respiratory Syncytial Virus Programs
U.S. STOCKS ON THE MOVE-Bath & Body Works, Buckle, Levi Strauss
U.S. STOCKS ON THE MOVE-YUM! Brands, LumiraDx, Clean Energy Tech
Enanta Pharmaceuticals up on fast-track tag from FDA for RSV drug
Brief: Enanta Pharmaceuticals Receives FDA Fast Track Designation For EDP-323
Brief: Enanta Pharmaceuticals To Present Data At The 33Rd European Congress Of Clinical Microbiology And Infectious Diseases
Brief: Enanta Pharmaceuticals Inc - Phase 1 Data Presented Continue To Highlight EDP-235'S Promising Overall Safety, Tolerability, Pharmacokinetic Profile